Breaking News, Financial News

Financial Report: Valeant

Dermatology sales were up 70% in the quarter

Valeant
 
4Q Revenues: $2.3 billion (+10%)

4Q Earnings: $534.1 million (earnings were $125.0 million 4Q13)

FY Revenues: $8.3 billion (+43%)

FY Earnings: $ 912.2 million (loss of 863.6 million FY13)

Comments: Dermatology sales were up 70% in the quarter to $424.7 million. Consumer sales were $141.4 million, up 6%. Ophthalmology Rx sales were $131.8 million, up 8%. Other/Generics sales were $452.9 million, up 28%. Restructuring, integration and other acquisition related costs were $47 million in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters